LEADER 01698nam  2200349   450 
001 9910688456203321
005 20230630044620.0
035   $a(CKB)5400000000044771
035   $a(NjHacI)995400000000044771
035   $a(EXLCZ)995400000000044771
100   $a20230630d2021      uy             0
101 0 $aeng
135   $aur|||||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aAdvances in Precision Medicine Oncology /$fHilal Arnouk, Bassam Hassan, editor
210  1$aLondon :$cIntechOpen,$d2021.
215   $a1 online resource (260 pages)
311   $a1-83968-869-6 
330   $aRecent advances in precision medicine and immuno-oncology have led to highly specific and efficacious cancer therapies such as monoclonal antibodies and immune checkpoint inhibitors (ICIs). This book provides an up-to-date overview of advances in the field of immuno-oncology. Chapters cover such topics as ICIs and how they mount a robust immune response against cancer cells as well as the response of ICIs to treatment predictive biomarkers and their potential immune-related adverse events (irAEs). Additionally, the book includes a comprehensive review of the powerful FDA-approved therapeutic agent doxorubicin, highlighting the molecular mechanisms behind doxorubicin's drug resistance and critical side effects.
606   $aCancer$xTreatment
615  0$aCancer$xTreatment.
676   $a616.99406
702   $aHassan$b Bassam
702   $aArnouk$b Hilal
801  0$bNjHacI
801  1$bNjHacl
906   $aBOOK
912   $a9910688456203321
996   $aAdvances in Precision Medicine Oncology$92828415
997   $aUNINA